Home Cell Cycle Wee1

Wee1 Inhibitors

Wee1 Products

  • All (7)
  • Wee1 Inhibitors (6)
  • New Wee1 Products
Cat.No. Product Name Information Product Use Citations Product Validations
S1525 Adavosertib (MK-1775) Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; this compound hinders G2 DNA damage checkpoint. Phase 2.
Cancer Cell, 2025, 43(8):1530-1548.e9
Nat Cancer, 2025, 10.1038/s43018-025-00960-z
Cell Rep Med, 2025, S2666-3791(25)00102-8
Verified customer review of Adavosertib (MK-1775)
S8148 PD0166285 PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). This compound is also a novel G2 checkpoint abrogator. It induces apoptosis.
iScience, 2025, 28(5):112292
Signal Transduct Target Ther, 2024, 9(1):181.
Nat Commun, 2024, 15(1):2089
F0602 Phospho-Wee1 (Ser642) Antibody [P3A10]
S9778 Debio 0123 WEE1-IN-5 (Debio 0123) is a potent Wee1 inhibitor that inhibits phospho-CDC2 and abrogates the G2 check point.
J Clin Invest, 2025, 135(11)e188165
medRxiv, 2024, 2023.05.17.23290140
E1000 Azenosertib (Zn-C3) Azenosertib (Zn-C3) is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.
bioRxiv, 2025, 2025.05.28.656693
medRxiv, 2024, 2023.05.17.23290140
E1175 lunresertib (RP-6306) Lunresertib (RP-6306) is a Protein Kinase, Membrane Associated Tyrosine/Threonine 1 (PKMYT1) inhibitor, and it can be used for the research of cancer.
Cell Rep, 2025, 44(8):116019
BMC Cancer, 2024, 24(1):1333
E4737New Potrasertib Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.
S1525 Adavosertib (MK-1775) Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; this compound hinders G2 DNA damage checkpoint. Phase 2.
Cancer Cell, 2025, 43(8):1530-1548.e9
Nat Cancer, 2025, 10.1038/s43018-025-00960-z
Cell Rep Med, 2025, S2666-3791(25)00102-8
 Verified customer review of Adavosertib (MK-1775)
S8148 PD0166285 PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). This compound is also a novel G2 checkpoint abrogator. It induces apoptosis.
iScience, 2025, 28(5):112292
Signal Transduct Target Ther, 2024, 9(1):181.
Nat Commun, 2024, 15(1):2089
S9778 Debio 0123 WEE1-IN-5 (Debio 0123) is a potent Wee1 inhibitor that inhibits phospho-CDC2 and abrogates the G2 check point.
J Clin Invest, 2025, 135(11)e188165
medRxiv, 2024, 2023.05.17.23290140
E1000 Azenosertib (Zn-C3) Azenosertib (Zn-C3) is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.
bioRxiv, 2025, 2025.05.28.656693
medRxiv, 2024, 2023.05.17.23290140
E1175 lunresertib (RP-6306) Lunresertib (RP-6306) is a Protein Kinase, Membrane Associated Tyrosine/Threonine 1 (PKMYT1) inhibitor, and it can be used for the research of cancer.
Cell Rep, 2025, 44(8):116019
BMC Cancer, 2024, 24(1):1333
E4737New Potrasertib Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.
E4737New Potrasertib Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.

Signaling Pathway Map